Advitech Announces That Cothera Confirms the Introduction of Dermylex 'TM' in France.

QUEBEC CITY, Quebec -- Advitech Inc. (TSX VENTURE:AVI) today announced that Cothera s.a has confirmed its intent to introduce and market Dermylex(TM) in France in September 2006, after securing the appropriate authorizations from the French Regulatory Office (the "AFFSA") to ensure compliance of Dermylex(TM) as an OTC product in France.The introduction will take place in September 2006.

Therefore Advitech and Cothera have entered in discussions for the conclusion of a definitive agreement in principle by April 30th 2006.The terms defining the scope of the definitive agreement was part of the principle agreement signed December 19th, 2005.The definitive agreement will grant Cothera exclusive rights to market Dermylex(TM) in specific segments of the French dermatology market. It will also stipulate minimum purchase level that Cothera must achieve in order to maintain its exclusivity. In addition, Cothera will implement a marketing program including specific dermatologists coverage objectives in France.

Commenting on the news, Renaud Beauchesne, CEO of Advitech, said "We are pleased with Cothera's success regarding the acceptability of Dermylex(TM) by the AFFSA and with their strategy to quickly introduce Dermylex (TM) in this market."

Francois Miceli, president of Cothera, added: "We have been able to work in a very proactive way with Advitech to secure the appropriate authorizations under our regulatory system and by doing so, we will be able to launch Dermylex in the French Market in September 2006."

About Cothera

Cothera is a company headed by three former senior executives from large pharmaceutical companies. Francois Miceli, one of its co-founders and its non-executive Chairman, is the former CEO of IDEXX Laboratories Italia, a subsidiary of IDEXX Laboratories (NASDAQ: IDXX). Dominique Bourgeade, co-founder and Chief Operating Officer, is the former Head of the pharmaceutical division of Pharmacia France, a company now part of Pfizer (NYSE: PFE). J.C. Anton, co-founder and Chief Scientific Officer, was previously Marketing Director of Pierre Fabre Laboratories

COTHERA(R) s.a.s. (www.cothera.com) is a French-based company which develops, manufactures and markets proprietary nutraceutical formulations to people at risk or suffering from neurodegenerative and/or chronic diseases through health care professionals, as a complementary integrated medicine, that is, one given in conjunction with allopathic treatment.

COTHERA(R) is dedicated to improving patient quality of life/care by providing scientific and clinically- backed nutraceuticals formulated in collaboration with leading physicians who focus on specific "patient" situations, recommended/initiated by doctors, and delivered directly to the customer/patient.

About Dermylex(TM)

Dermylex(TM) is Advitech's orally administered product for mild to moderate plaque psoriasis. Dermylex(TM) is based on Advitech's XP-828L, a bioactive ingredient with proven clinical efficacy.On July 5, 2005, the Company reported positive results from its Phase II clinical trial of XP-828L for treating mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of XP-828L for treating mild to moderate psoriasis.

About Advitech

Advitech is a Canadian biotechnology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (IMID), such as psoriasis and inflammatory bowel diseases. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the ad equacy or accuracy of this release.

Advitech Inc. (TSX VENTURE:AVI)